174180-78-0

Usage

Molecular structure

A derivative of 1H-indazole with a carboxylic acid group, an ethyl ester group, and a tetrahydro-1-(phenylmethyl) group.

Heterocyclic compound

Contains a ring structure with one or more non-carbon atoms, in this case, an indazole ring.

Potential drug or pharmaceutical intermediate

The presence of a carboxylic acid and ethyl ester group suggests its potential use in drug development or as a building block for more complex molecules.

Psychoactive or central nervous system effects

The 4,5,6,7-tetrahydro-1-(phenylmethyl) group resembles the structure of certain neurotransmitters and neuromodulators, indicating possible effects on the CNS.

Potential uses

The compound may be used in drug development, as a research tool in pharmacology, or in neuroscience studies.

Chemical classification

Belongs to the class of organic compounds known as indole derivatives.

Upstream product

• 5396-14-5 ethyl 2-oxo-2-(2-oxocyclohexyl)acetate 
• 20570-96-1 benzylhydrazine dihydrochloride 
• 100-39-0 benzyl bromide 
• 584-08-7 potassium carbonate 
• 4492-02-8 ethyl 4,5,6,7-tetrahydro-1H-indazole-3-carboxylate 

Downstream Products

• 174180-79-1 2-[2,4-Dioxo-5-phenyl-3-(4,5,6,7-tetrahydro-1-benzyl-1H-indazol-3-ylmethyl)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxyphenyl)-acetamide 
• 174180-38-2 1-Benzyl-3-bromomethyl-4,5,6,7-tetrahydro-1H-indazole 
• 82071-69-0 1-Benzyl-3-hydroxymethyl-4,5,6,7-tetrahydro-1H-indazole 

Relevant academic research and scientific papers

Tetrahydro-indazole cannabinoid modulators

This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives

Benzo?b!?1,4!diazepine compounds of formula (I), where R1 is selected from C1 C6 alkyl, C3 -C6 cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3 -C6 alkyl, C3 C6 cycloalkyl, C3 -C6 alkenyl, benzyl, phenylC1 -C3 alkyl of substituted phenyl; or NR1 R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6 alkyl C1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6 alkyl; R4 is C1-6 alkyl or C1-6 alkenyl; R7 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6 R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).